Alta Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$470K Hold
7,750
0.17% 85
2025
Q4
$418K Sell
7,750
-2,400
-24% -$115K 0.15% 102
2025
Q3
$458K Hold
10,150
0.14% 117
2025
Q2
$470K Hold
10,150
0.17% 110
2025
Q1
$619K Buy
10,150
+3,400
+50% +$198K 0.26% 80
2024
Q4
$382K Buy
6,750
+1,250
+23% +$69.8K 0.24% 84
2024
Q3
$285K Hold
5,500
0.13% 100
2024
Q2
$228K Hold
5,500
0.11% 110
2024
Q1
$298K Hold
5,500
0.15% 83
2023
Q4
$282K Hold
5,500
0.15% 82
2023
Q3
$319K Hold
5,500
0.19% 64
2023
Q2
$352K Hold
5,500
0.2% 59
2023
Q1
$381K Hold
5,500
0.23% 52
2022
Q4
$396K Hold
5,500
0.24% 50
2022
Q3
$391K Buy
+5,500
New +$399K 0.25% 43

Other funds holding BMY

Alta Advisers's BMY Position: Q1 2026 in Review

Alta Advisers held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 7,750 shares worth $470K. The position accounts for 0.17% of the portfolio, ranked #85.

Alta Advisers first reported a position in BMY in Q3 2022 and has held it in 15 quarters since. The position peaked at $619K in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Alta Advisers held 7,750 shares of Bristol-Myers Squibb worth $470K as of Q1 2026.
  • Alta Advisers left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.17% of Alta Advisers's portfolio in Q1 2026, its #85 holding.
  • Alta Advisers first reported a position in Bristol-Myers Squibb in Q3 2022 and has held it in 15 quarters since.
  • Alta Advisers's Bristol-Myers Squibb position peaked at $619K in Q1 2025.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Alta Advisers's 13F filing for Q1 2026, filed 7 May 2026.